stockrowGilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.3%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) Return on invested capital
Gilead Sciences, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −4.51%, down 20.2 percentage points from fiscal 2025 (15.7%). Over the past ten years it has ranged from 2.89% (fiscal 2024) to 51.5% (fiscal 2015); the current reading is higher than 64% of that period. That is below the Drug Manufacturers General industry median of 6.26% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 15.7% | 12.80 |
| FY2024 | 2.89% | (8.49) |
| FY2023 | 11.4% | 0.27 |
| FY2022 | 11.1% | (3.57) |
| FY2021 | 14.7% | 8.82 |
| FY2020 | 5.86% | (5.35) |
| FY2019 | 11.2% | (14.66) |
| FY2018 | 25.9% | (4.47) |
| FY2017 | 30.3% | (1.97) |
| FY2016 | 32.3% | (19.14) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| AMGN Amgen Inc. compare | 14.3% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| AZN AstraZeneca PLC compare | 12.3% |
| NVS Novartis AG compare | 12.1% |
| SNY Sanofi compare | 7.05% |
| PFE Pfizer Inc. compare | 6.19% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement